Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
BackgroundEpstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.709370/full |
| id |
doaj-de9b8cafa2d0435a98f5e22dbc5cc567 |
|---|---|
| record_format |
Article |
| spelling |
doaj-de9b8cafa2d0435a98f5e22dbc5cc5672021-07-22T14:50:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-07-011110.3389/fonc.2021.709370709370Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative DisorderNan Yan0Na Wang1Na Wang2Peiling Zhang3Peiling Zhang4Gaoxiang Wang5Gaoxiang Wang6Xia Mao7Xia Mao8Dan Peng9Dong Kuang10Liting Chen11Liting Chen12Li Zhu13Li Zhu14Jianfeng Zhou15Jianfeng Zhou16Yicheng Zhang17Yicheng Zhang18Yang Cao19Yang Cao20Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, ChinaDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, ChinaBackgroundEpstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation and PTLD. However, reports on the curative management of refractory PTLD are scarce.Case PresentationIn this report, we describe the successful management of two patients with EBV-PTLD with chimeric antigen receptor T-cell (CAR-T) therapy.ConclusionThe present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings.https://www.frontiersin.org/articles/10.3389/fonc.2021.709370/fullCAR-THSCTPTLDEBVALL |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Nan Yan Na Wang Na Wang Peiling Zhang Peiling Zhang Gaoxiang Wang Gaoxiang Wang Xia Mao Xia Mao Dan Peng Dong Kuang Liting Chen Liting Chen Li Zhu Li Zhu Jianfeng Zhou Jianfeng Zhou Yicheng Zhang Yicheng Zhang Yang Cao Yang Cao |
| spellingShingle |
Nan Yan Na Wang Na Wang Peiling Zhang Peiling Zhang Gaoxiang Wang Gaoxiang Wang Xia Mao Xia Mao Dan Peng Dong Kuang Liting Chen Liting Chen Li Zhu Li Zhu Jianfeng Zhou Jianfeng Zhou Yicheng Zhang Yicheng Zhang Yang Cao Yang Cao Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder Frontiers in Oncology CAR-T HSCT PTLD EBV ALL |
| author_facet |
Nan Yan Na Wang Na Wang Peiling Zhang Peiling Zhang Gaoxiang Wang Gaoxiang Wang Xia Mao Xia Mao Dan Peng Dong Kuang Liting Chen Liting Chen Li Zhu Li Zhu Jianfeng Zhou Jianfeng Zhou Yicheng Zhang Yicheng Zhang Yang Cao Yang Cao |
| author_sort |
Nan Yan |
| title |
Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder |
| title_short |
Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder |
| title_full |
Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder |
| title_fullStr |
Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder |
| title_full_unstemmed |
Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder |
| title_sort |
case report: successful chimeric antigen receptor t cell therapy in haploidentical-allogeneic stem cell transplant patients with post-transplant lymphoproliferative disorder |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Oncology |
| issn |
2234-943X |
| publishDate |
2021-07-01 |
| description |
BackgroundEpstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation and PTLD. However, reports on the curative management of refractory PTLD are scarce.Case PresentationIn this report, we describe the successful management of two patients with EBV-PTLD with chimeric antigen receptor T-cell (CAR-T) therapy.ConclusionThe present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings. |
| topic |
CAR-T HSCT PTLD EBV ALL |
| url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.709370/full |
| work_keys_str_mv |
AT nanyan casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT nawang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT nawang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT peilingzhang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT peilingzhang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT gaoxiangwang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT gaoxiangwang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT xiamao casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT xiamao casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT danpeng casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT dongkuang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT litingchen casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT litingchen casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT lizhu casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT lizhu casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT jianfengzhou casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT jianfengzhou casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT yichengzhang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT yichengzhang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT yangcao casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder AT yangcao casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder |
| _version_ |
1721291258464305152 |